CONTACT: MARY SPAIGHT, R.N.
8th Floor John Pappajohn Pavilion
Iowa City IA 52242
UIHC selected to test two new breast cancer drugs
IOWA CITY, Iowa -- The University of Iowa Hospitals and Clinics (UIHC)
is one of 14 medical centers in the United States and Canada selected to
evaluate two drugs in the treatment of breast cancer.
This is phase two of the study evaluating the effectiveness of using
Adramycin and Taxotere in combination. The drugs are two of the most active
single agents for treating metastatic breast cancer. The current study
is designed to determine whether the drugs may be more effective in treating
breast cancer when used together.
The study is conducted by the National Surgical Adjuvant Breast and
Bowel Project and the National Cancer Institute. Surgical cancer specialist
Dr. Peter Jochimsen will direct the study at the UIHC.
The study is expected to be open to accept patients in late May. For
more information regarding the study, telephone the project coordinator,
Mary Spaight, R.N. at (319) 356-2778.